Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan;83(1):87-92.
doi: 10.1007/s40265-022-01821-0.

Ozoralizumab: First Approval

Susan J Keam  1
Affiliations
Review

Ozoralizumab: First Approval

Susan J Keam. Drugs. 2023 Jan.

Abstract

Ozoralizumab (Nanozora®), a trivalent anti-tumour necrosis factor alpha (TNFα) NANOBODYⓇ compound, has been developed by Taisho Pharmaceutical Co. Ltd (under license from Ablynx, an affiliate of Sanofi) for the treatment of rheumatoid arthritis (RA). In September 2022, ozoralizumab was approved in Japan for the treatment of RA that is inadequately managed by current available treatments. This article summarizes the milestones in the development of ozoralizumab leading to this first approval.

PubMed Disclaimer

References

    1. McInnes IB, Buckley CD, Isaacs JD. Cytokines in rheumatoid arthritis: shaping the immunological landscape. Nat Rev Rheumatol. 2016;12(1):63–8. - DOI
    1. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108–23. - DOI
    1. Kawahito Y, Morinobu A, Kaneko Y, et al. Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis: secondary publication. Mod Rheumatol. 2022. https://doi.org/10.1093/mr/roac017 . - DOI
    1. Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–99. - DOI
    1. Taisho Pharmaceutical Company Ltd. Ozoralizumab (Nanozora®): Japanese prescribing information. 2022. http://medical.taisho.co.jp/di/brand/nz/product.php?bdname=nz&brand=nz . Accessed 20 Oct 2022

MeSH terms

Substances

LinkOut - more resources